Background. Diffuse large B-cell lymphoma (DLBCL) is an aggressive B-cell lymphoma with high heterogeneity. There is an unmet need to investigate valid indicators for the diagnosis and therapy of DLBCL. Methods. GEO database was utilized to screen for differentially expressed genes (DEGs) and differential miRNAs in DLBCL tissues. The Gene Ontology (GO) and the Kyoto Encyclopedia of Genes and Genomes (KEGG) were applied to analyse DEGs. Then multiple databases were searched for related miRNAs within DLBCL, TNF receptor-associated factor 5 (TRAF5) and NF-kappa B (NF-κB) signaling pathways. The KOBAS database was used to assist in the screening of miRNAs of interest and construct the regulatory network of miRNA-mRNA. Finally, the expression le...
Introduction: The expression patterns of microRNAs in plasma are involved in potential biomarkers fo...
Accurate lymphoma diagnosis, prognosis and therapy still require additional markers. We explore the ...
Diffuse large B cell lymphoma (DLBCL) treatment with R-CHOP regimen produces 5-year progression-free...
Deregulation of microRNA (miRNA) expression has been documented in diffuse large B-cell lymphoma (DL...
AbstractMicroRNAs (miRNAs) are small endogenous RNA molecules that regulate gene expression at the p...
MicroRNA is a small non-coding RNA (sncRNA) involved in gene silencing and regulating post-transcrip...
Diffuse large B cell lymphoma (DLBCL) is the most common subtype of invasive non-Hodgkin's lymphoma ...
Abstract Despite being considered a single disease, Diffuse Large B Cell Lymphoma (DLBCL) presents w...
We studied the global miRNA expression in diffuse large B-cell lymphoma (DLBCL; n=79), Burkitt lymph...
Background Diffuse large B-cell lymphoma (DLBCL) is a highly heterogeneous malignancy with varied ou...
International audienceMicroRNA (miRNA) have been emerged as prognostic biomarkers in diffuse large B...
The activated B cell (ABC) and germinal center B cell (GCB) subtypes of diffuse large B cell lymphom...
Diffuse large B cell lymphoma (DLBCL) treatment with R-CHOP regimen produces 5-year progression-free...
Despite better therapeutic options and improved survival of diffuse large B-cell lymphoma (DLBCL), 3...
MicroRNAs are naturally occurring small RNA species that regulate gene expression and are frequently...
Introduction: The expression patterns of microRNAs in plasma are involved in potential biomarkers fo...
Accurate lymphoma diagnosis, prognosis and therapy still require additional markers. We explore the ...
Diffuse large B cell lymphoma (DLBCL) treatment with R-CHOP regimen produces 5-year progression-free...
Deregulation of microRNA (miRNA) expression has been documented in diffuse large B-cell lymphoma (DL...
AbstractMicroRNAs (miRNAs) are small endogenous RNA molecules that regulate gene expression at the p...
MicroRNA is a small non-coding RNA (sncRNA) involved in gene silencing and regulating post-transcrip...
Diffuse large B cell lymphoma (DLBCL) is the most common subtype of invasive non-Hodgkin's lymphoma ...
Abstract Despite being considered a single disease, Diffuse Large B Cell Lymphoma (DLBCL) presents w...
We studied the global miRNA expression in diffuse large B-cell lymphoma (DLBCL; n=79), Burkitt lymph...
Background Diffuse large B-cell lymphoma (DLBCL) is a highly heterogeneous malignancy with varied ou...
International audienceMicroRNA (miRNA) have been emerged as prognostic biomarkers in diffuse large B...
The activated B cell (ABC) and germinal center B cell (GCB) subtypes of diffuse large B cell lymphom...
Diffuse large B cell lymphoma (DLBCL) treatment with R-CHOP regimen produces 5-year progression-free...
Despite better therapeutic options and improved survival of diffuse large B-cell lymphoma (DLBCL), 3...
MicroRNAs are naturally occurring small RNA species that regulate gene expression and are frequently...
Introduction: The expression patterns of microRNAs in plasma are involved in potential biomarkers fo...
Accurate lymphoma diagnosis, prognosis and therapy still require additional markers. We explore the ...
Diffuse large B cell lymphoma (DLBCL) treatment with R-CHOP regimen produces 5-year progression-free...